DK3801536T3 - Indgivelse af sepiapterin uden mad til anvendelse i en fremgangsmåde til at øge sepiapterinplasmaeksponering - Google Patents

Indgivelse af sepiapterin uden mad til anvendelse i en fremgangsmåde til at øge sepiapterinplasmaeksponering Download PDF

Info

Publication number
DK3801536T3
DK3801536T3 DK19811888.7T DK19811888T DK3801536T3 DK 3801536 T3 DK3801536 T3 DK 3801536T3 DK 19811888 T DK19811888 T DK 19811888T DK 3801536 T3 DK3801536 T3 DK 3801536T3
Authority
DK
Denmark
Prior art keywords
sepiapterin
administration
food
increasing
plasma exposure
Prior art date
Application number
DK19811888.7T
Other languages
Danish (da)
English (en)
Inventor
Neil Smith
Jonathan Reis
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Application granted granted Critical
Publication of DK3801536T3 publication Critical patent/DK3801536T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK19811888.7T 2018-05-30 2019-05-30 Indgivelse af sepiapterin uden mad til anvendelse i en fremgangsmåde til at øge sepiapterinplasmaeksponering DK3801536T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US201962822376P 2019-03-22 2019-03-22
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Publications (1)

Publication Number Publication Date
DK3801536T3 true DK3801536T3 (da) 2024-08-19

Family

ID=68699037

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19811888.7T DK3801536T3 (da) 2018-05-30 2019-05-30 Indgivelse af sepiapterin uden mad til anvendelse i en fremgangsmåde til at øge sepiapterinplasmaeksponering

Country Status (20)

Country Link
US (3) US11617752B2 (cg-RX-API-DMAC7.html)
EP (2) EP3801536B1 (cg-RX-API-DMAC7.html)
JP (2) JP7502197B2 (cg-RX-API-DMAC7.html)
CN (1) CN112703002A (cg-RX-API-DMAC7.html)
AU (2) AU2019277382B2 (cg-RX-API-DMAC7.html)
CA (1) CA3102106A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801536T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986920T3 (cg-RX-API-DMAC7.html)
FI (1) FI3801536T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241213T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068589T2 (cg-RX-API-DMAC7.html)
LT (1) LT3801536T (cg-RX-API-DMAC7.html)
MD (1) MD3801536T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020012979A (cg-RX-API-DMAC7.html)
PL (1) PL3801536T3 (cg-RX-API-DMAC7.html)
PT (1) PT3801536T (cg-RX-API-DMAC7.html)
RS (1) RS65874B1 (cg-RX-API-DMAC7.html)
SI (1) SI3801536T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400430T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019232130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
EP3213062B1 (en) * 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN111328414B (zh) * 2017-11-23 2022-09-23 株式会社半导体能源研究所 显示装置及电子设备
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) * 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Also Published As

Publication number Publication date
EP3801536A1 (en) 2021-04-14
AU2019277382B2 (en) 2025-01-09
EP3801536A4 (en) 2022-03-23
US12329757B2 (en) 2025-06-17
JP2024069192A (ja) 2024-05-21
CN112703002A (zh) 2021-04-23
MX2020012979A (es) 2021-04-29
US20230381181A1 (en) 2023-11-30
RS65874B1 (sr) 2024-09-30
AU2025200814A1 (en) 2025-02-27
EP3801536B1 (en) 2024-07-17
HUE068589T2 (hu) 2025-01-28
MD3801536T2 (ro) 2024-11-30
PL3801536T3 (pl) 2025-02-03
US20210220363A1 (en) 2021-07-22
JP2021525729A (ja) 2021-09-27
HRP20241213T1 (hr) 2024-11-22
US20260091037A1 (en) 2026-04-02
EP4454704A2 (en) 2024-10-30
FI3801536T3 (fi) 2024-08-29
ES2986920T3 (es) 2024-11-13
EP4454704A3 (en) 2025-01-01
JP7502197B2 (ja) 2024-06-18
MX2024005935A (es) 2024-06-04
PT3801536T (pt) 2024-09-19
JP7841005B2 (ja) 2026-04-06
LT3801536T (lt) 2024-09-25
WO2019232130A1 (en) 2019-12-05
SMT202400430T1 (it) 2024-11-15
AU2019277382A1 (en) 2021-01-21
CA3102106A1 (en) 2019-12-05
US11617752B2 (en) 2023-04-04
SI3801536T1 (sl) 2024-12-31

Similar Documents

Publication Publication Date Title
SI3801536T1 (sl) Dajanje sepiapterina brez hrane za uporabo v postopku za zvišanje plazemske izpostavljenosti sepiapterinu
DK3602966T3 (da) Probabilistisk grundårsagskorrelation i realtid af netværksfejl
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
DK3566276T3 (da) Fremgangsmåde til drift af en deltager i et forsyningsnet
DK3435996T3 (da) Elafibranor til anvendelse i behandlingen af primær biliær cholangitis
IL282240A (en) Inhibitors of human immunodeficiency virus replication
DK3275438T3 (da) Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
DK3463498T3 (da) Plasmabaserede film og fremgangsmåder til fremstilling og anvendelse af den samme.
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3490398T3 (da) Fremgangsmåde til anvendelse af et sæt vippeextensions
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
DK3410858T3 (da) System til opbevaring og dosering af ingredienser og fremgangsmåde for dosering og afsætning af ingredienser på et substrat
DK3292153T3 (da) Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling
DK3310389T3 (da) Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis
DK3436435T3 (da) Substituerede indolderivater som inhibitorer af replikation af denguevirus
PT3870575T (pt) Inibidores da replicação do vírus da imunodeficiência humana
DK3826639T3 (da) Optimeret dosering af diaminophenothiaziner i populationer
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3801534T3 (da) Behandling af fenylketonuri med sepiapterin
DK3302549T3 (da) Kombinationsbehandling af et anti-CD20-antistof med en Bcl-2-inhibitor og en MDM2-inhibitor
DK3347342T3 (da) Fremgangsmåde til fremstilling af biguanidin-salte og s-triaziner
DK3497403T3 (da) Geolokalisering af personer baseret på et afledt socialt netværk
DK3149000T3 (da) Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer
DK3463328T3 (da) Seladelpar til behandling af primær biliær cholangitis
DK3512846T3 (da) Ketonhæmmere af lysin-gingipain